Clinical trials: Obese Adults
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity and Overweight
A Study of MET233 in Individuals With Obesity or Overweight
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.
- Trial name
- NCT07022977
- Testing
- MET233
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Diabetes Mellitus, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control.
- Trial name
- NCT05579977
- Testing
- PF-07081532, Rybelsus
- Where
- 90 sites in United States, Bulgaria and 6 more
- Volunteers
- 902 people
- Sponsor
- Pfizer
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Obesity, Type 2 Diabetes Mellitus (T2DM)
Magnetic Duodeno-Ileal Chile Study
The objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06613724
- Testing
- Magnet System, DI Biofragmentable
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Overweight and Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
- Trial name
- EMBRAZE (NCT06445075)
- Testing
- Apitegromab, Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Scholar Rock, Inc.
Obesity or Overweight
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with…
- Trial name
- ZYNERGY (NCT07589686)
- Testing
- Petrelintide, Enicepatide
- Volunteers
- 486 people
- Sponsor
- Hoffmann-La Roche
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Obesity
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study…
- Trial name
- NCT00796367
- Testing
- VI-0521
- Volunteers
- 676 people
- Sponsor
- VIVUS LLC
Obesity, Overweight
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05669599
- Testing
- Maridebart Cafraglutide
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 592 people
- Sponsor
- Amgen
Obese Adults
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Background: Obesity affects 18.1% of adults in France and leads to numerous chronic complications as well as functional limitations (fatigability, dyspnea).
- Trial name
- ON-TRAC (NCT07903025)
- Testing
- Axomove Therapy, Standard multidisciplinary medical care
- Where
- 8 sites in France
- Volunteers
- 184 people
- Sponsor
- Axomove
Obesity
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition in which a person has too much body fat, which can harm their health and increase…
- Trial name
- NCT07794774
- Testing
- Berobenatide
- Where
- 28 sites in Japan
- Volunteers
- 197 people
- Sponsor
- Pfizer
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background…
- Trial name
- ENLIGHTEN-6 (NCT07392190)
- Testing
- Eloralintide
- Where
- 185 sites in United States, Australia and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company